Close
Smartlab Europe
Inizio Ignite

Clinical Trials

Clinical Trial of Ayurvedic Remedy For COVID-19 Shows Groundbreaking Results

A groundbreaking interim report on a clinical trial being conducted in three hospitals has shown that Covid-19 patients on natural treatment are resolving most symptoms earlier than those on conventional medicines. The interim report on combination treatment of an Ayurvedic...

Veeva and Bioforum Partner with RedHill Biopharma to Maximize Value of Opaganib Phase 2/3 COVID-19 Clinical Data

Veeva Systems and Bioforum announced their collaboration with RedHill Biopharma Ltd. on a global Phase 2/3 clinical study evaluating opaganib (Yeliva®, ABC294640),1 a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, in patients hospitalized with severe COVID-19 pneumonia requiring treatment...

Bharat Biotech to collaborate with Washington University School of Medicine on COVID-19 nasal vaccine

Vaccine maker Bharat Biotech has entered into an agreement with Washington University School of Medicine in St. Louis as part of which it will conduct trials, produce and market an intranasal vaccine for COVID-19 being developed by the latter. It...

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

Johnson & Johnson announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from...

I-Mab receives China NMPA clearance to begin phase 1 trial of lemzoparlimab in relapsed/refractory advanced lymphoma

I-Mab, a clinical stage biopharmaceutical company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for lemzoparlimab (also known as TJC4) to initiate a...

RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron’s REGN-COV2 Investigational Antibody Cocktail in the UK

Regeneron Pharmaceuticals, Inc. and the University of Oxford today announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world's largest randomized clinical trials of potential COVID-19 treatments, will evaluate Regeneron's investigational anti-viral antibody cocktail, REGN-COV2. The Phase...

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 Neutralizing Antibody in COVID-19 Positive Patients

Sorrento Therapeutics, Inc. announced that it received a study may proceed letter from the FDA for its phase 1 clinical trial for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients. As Sorrento previously announced, in preclinical studies, STI-1499 demonstrated 100% in vitro...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »